Oncology/Cancer Drugs Market to Reach $176.50 Bn, Globally, by 2025 at 7.6% CAGR

The global oncology/cancer drugs market generated $97.40 billion in 2017, and is estimated to reach $176.50 billion by 2025, growing at a CAGR of 7.6% from 2018 to 2025.

Surge in incidence of cancer across the globe and considerable rise in expenditure on healthcare services by governments facilitate the growth in the global oncology/cancer drugs market. However, fatal effects related to cancer drugs usage hinder the market growth. On the other hand, surge in number of pipeline drugs and untapped potential in emerging countries offer lucrative opportunities in the industry.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/121

Based on drug class type, the targeted therapy and chemotherapy segments together accounted for nearly three-fourths of the total market share in 2017, and is expected to maintain dominance in the cancer drugs industry throughout the forecast period. Contrarily, the immunotherapy segment is estimated to register the highest growth rate with a CAGR of 10.4% from 2018 to 2025, owing to higher rates of survival and remission related to their use.

Based on indication, the lung cancer segment is estimated to register the largest CAGR of 11.7% from 2018 to 2025, owing to considerable surge in prevalence across the world. On the other hand, the kidney, breast, and prostate cancer segments together contributed to two-fifths of the total market share in 2017 and is expected to continue its leadership status during the forecast period.

Based on region, Asia-Pacific is projected to grow at the highest rate, registering a CAGR of 9.5% from 2018 to 2025. This is owing to huge base of population and advanced healthcare infrastructure. North America and Europe together accounted for nearly three-fourths of the total market share in 2017, and will maintain their dominance by 2025, owing to rise in awareness regarding advanced therapies, growth in sedentary lifestyle, and ease in accessibility to premiere chemotherapy treatments.

For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/121

Leading market players discussed in the research are Amgen Inc., Celgene Corporation, Eli Lilly and Company, Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Pfizer Inc., Merck & Co., Inc., and Sanofi.

Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research/

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.